Susceptibility-guided combination therapy improves neurological status and reduces abscess size in a patient with nocardiosis
Case report: Brain infection in autoimmune hepatitis patient
This case report describes the management of disseminated nocardiosis in a 55-year-old man with autoimmune hepatitis. The patient showed gra…
A man with autoimmune hepatitis developed a rare brain infection after immunosuppression. Doctors treated it successfully with targeted anti…
Piezoelectric osteotomy reduces edema, ecchymosis, and pain in patients undergoing rhinoplasty
Piezoelectric tools reduce swelling and bruising after nose surgery
This meta-analysis of 905 patients found that piezoelectric osteotomy significantly reduces postoperative edema, ecchymosis, and pain compar…
New research shows that using piezoelectric tools during nose surgery can significantly lower pain, bruising, and swelling for patients.
Acupuncture Modalities Show Distinct Benefits for Trigeminal Neuralgia
New analysis shows acupuncture and bloodletting help trigeminal neuralgia
A network meta-analysis of 58 RCTs finds bloodletting therapy improves total effective rate and pain scores, while acupuncture combined with…
New research highlights how specific acupuncture techniques and bloodletting can reduce pain and attack frequency for those with trigeminal …
FDA Approves Sarclisa Escena (isatuximab-irfc) Subcutaneous for Multiple Myeloma
FDA approves new multiple myeloma drug Sarclisa Escena for injection under the skin.
The FDA approved Sarclisa Escena (isatuximab-irfc) subcutaneous injection for multiple myeloma in three combination regimens. It is indicate…
The FDA approved Sarclisa Escena (isatuximab-irfc) for subcutaneous injection to treat multiple myeloma. It can be used in three different d…
Immune microenvironment characterization provides a framework for precision immunotherapy in various thyroid cancer types
New Model Identifies Immune Pathways in Thyroid Cancer Treatment
This systematic review synthesizes the immune evolution of thyroid cancer from autoimmune-driven inflammation to exhausted states in advance…
A new framework maps how immune cells change in thyroid cancer, helping researchers identify better ways to target tumors and overcome treat…
Vivaray Hb pro shows 1.5 g/dL mean absolute error in hemoglobin measurement
Handheld device shows promise for quick blood tests
This cross-sectional diagnostic accuracy study evaluated the Vivaray Hb pro device against a calibrated laboratory blood cell counter in 763…
A new handheld device can measure hemoglobin levels quickly without needles, offering a faster way to screen patients in many different sett…
Efgartigimod PH20 SC showed no significant difference versus placebo in primary ITP
Trial Shows Efgartigimod Results for Immune Thrombocytopenia Patients
This Phase 3 randomized controlled trial evaluated efgartigimod PH20 SC in 207 adults with primary immune thrombocytopenia and platelet coun…
A Phase 3 trial found that the drug efgartigimod did not show a significant difference in platelet counts compared to a placebo.
Venetoclax plus intensive chemo yields 63.79% ORR in relapsed/refractory AML meta-analysis
Venetoclax combo shows promise for hard-to-treat leukemia
A meta-analysis of 235 patients with relapsed/refractory AML found that venetoclax combined with intensive chemotherapy achieved a pooled ov…
For patients with relapsed AML, venetoclax plus intensive chemo led to a 64% response rate in a new analysis.
Avatrombopag shows 80.0% response rate and 2.82% thromboembolic event rate in adult immune thrombocytopenia
Blood clot risk with avatrombopag for immune thrombocytopenia: real-world data
This systematic review and meta-analysis evaluates avatrombopag for adult primary immune thrombocytopenia using real-world data. The analysi…
A new analysis finds avatrombopag works well for low platelets, but about 3% of patients had blood clots. Real-world data from 1,000+ adults…
FDA Approves Besremi (interferon alfa-2b) for Polycythemia Vera
FDA approves new treatment for rare blood disorder polycythemia vera
The FDA approved Besremi (interferon alfa-2b) for adults with polycythemia vera. It is administered subcutaneously every two weeks, with dos…
The FDA approved Besremi (interferon alfa-2b) for adults with polycythemia vera, a condition where the body makes too many red blood cells. …
AI-augmented screening improves hereditary hemolytic anemia detection with 92.8% pooled sensitivity
AI tools improve accuracy for screening hereditary blood disorders
This meta-analysis of 133,498 individuals screened for hereditary hemolytic anemia (HHA) carriers found that AI-augmented complete blood cou…
New data shows that adding artificial intelligence to blood tests can better identify people carrying genes for conditions like sickle cell …
Low-dose ATG plus PTCy shows no significant difference in acute GVHD compared to standard regimens
Trial Shows New Treatment Strategy for Leukemia Stem Cell Transplant
This randomized trial of 407 patients with AML or MDS undergoing haploidentical transplant found that low-dose ATG plus PTCy did not signifi…
A new combination of medications may help patients recover blood cells faster after a stem cell transplant for leukemia or blood disorders.